Craif

Meet an Unreasonable Venture

Realising a society where people can live out their natural lives.

Ryuichi Onose

Cofounder & CEO at Craif

More about Ryuichi »

Connect

craif.comen/

Employees 51–100

Headquarters Tokyo, Japan

Craif is a molecular diagnostics company harnessing the power of miRNA and machine learning to develop an early detection classifier. Our proprietary miRNA platform and sampling technology enable the capture of low-expression RNA, facilitating the development of assays that accurately predict early-stage cancer. In 2022, Craif launched its miSignal multi-cancer early detection assay in Japan, covering seven cancer types (pancreatic, ovarian, oesophageal, lung, breast, colorectal, and gastric).

Craif USA was established in 2023 to introduce this platform to the US market, with a focus on pancreatic cancer. We are currently enrolling cancer patients and high-risk controls for US population validation of the assay. Craif USA is also developing a portfolio strategy tailored to the unmet clinical needs and competitive landscape of the US.

Health

Notable Achievements

Raised over US$33 million including equity, debt and grants
Launched miSignal", a multiple early cancer detection test in Japan, with annual sales growth of 500-600%
Pancreatic cancer clinical trial for PMDA (equivalent to FDA) approval to start in 2024

Currently Operating in One Region

Press Mentions

May 27, 2024

Unreasonable Impact announces new roster of ventures for Asia Pacific programme

The story discusses the launch of a new online platform called "The Good Influence" that aims to promote positive content and combat misinformation on social media. It highlights the platform's...

Read on WebWire »

May 23, 2024

Unreasonable Impact announces new roster of ventures for Asia Pacific programme

Singapore, Friday 24 May 2024: Unreasonable Impact, a strategic partnership between Unreasonable Group and Barclays, has announced the latest ventures to join its Asia Pacific programme. This...

Read on Unreasonable »